Wenjian Zeng¹, Xianglong Li², Hao Cai¹, Qingyu Zhou², Shuangshuang Sun², Pingping Li², Sunlong Li¹, Zhi Chen^2,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.073934 - 21 May 2026

Abstract Objectives: Cisplatin resistance is a major obstacle in the treatment of renal cell carcinoma (RCC), severely compromising therapeutic efficacy and patient prognosis. This study aimed to clarify the role and molecular mechanism of cyclin-dependent kinase 4 (CDK4) in cisplatin resistance of RCC. Methods: Immunohistochemistry (IHC) was used to detect the expression of CDK4 in cisplatin-resistant RCC tissues. In RCC cells and their drug-resistant sublines, CDK4 overexpression/knockdown assays were performed to evaluate the effects on cisplatin resistance and malignant progression. An in vivo model was established, to verify the in vivo function of CDK4. Transcriptome sequencing (RNA-seq), Cleavage Under… More >

Antonio Ruggiero^1,2,*, Fernando Fuccillo¹, Valerio Di Paola³, Alberto Romano¹, Palma Maurizi^1,2, Dario Talloa¹, Nazario Foschi⁴, Pierluigi Russo⁴, Marco Racioppi⁴, Stefano Mastrangelo^1,2, Giorgio Attinà¹

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.072807 - 23 March 2026

Abstract Background: The management of renal neoplasms in adolescent patients poses unique clinical challenges due to their transitional position between paediatric and adult populations. This age group exhibits marked heterogeneity in tumour histology, ranging from entities commonly observed in paediatric oncology to tumours typical of adult age, as well as rare histological subtypes that exceptionally affect the kidney. Given the substantial differences in clinical protocols between paediatric and adult populations, rigorous multidisciplinary evaluation is essential to determine optimal diagnostic and therapeutic strategies for adolescent patients. Case Description: We present four cases from our tertiary referral centre that… More >

HONGYAN LI^1,#, CHUNLING LIAO^2,#, WENJUAN WENG², HONGZHEN ZHONG², TIANBIAO ZHOU^2,*

BIOCELL, Vol.44, No.2, pp. 257-262, 2020, DOI:10.32604/biocell.2020.08826 - 27 May 2020

Abstract In this study, we used a meta-analysis method to evaluate the relationship between hypoxia-inducible factor-1α (HIF1α) 1772C/T gene polymorphism (rs 11549465) and renal cell carcinoma (RCC)/prostate cancer risk. We searched for relevant studies (before March 1, 2019) on Cochrane Library, Embase, and PubMed. Studies meeting the inclusion criteria were recruited into this meta-analysis. The outcome of dichotomous data was showed in the way of odds ratios (OR), and 95% confidence intervals (CI) were also counted. In this investigation, there was no association between HIF1α 1772C/T gene polymorphism and susceptibility to RCC in Caucasians, Asians as More >

Gang Li^*, Tie Chong^*, Jie Yang^†, Hongliang Li^*, Haiwen Chen^*

Oncology Research, Vol.27, No.1, pp. 125-137, 2019, DOI:10.3727/096504018X15213115046567

Abstract KIFC1 (kinesin family member C1) plays a critical role in clustering of extra centrosomes in various cancer cells and thus could be considered as a promising therapeutic target. However, whether KIFC1 is involved in the procession of renal cell carcinoma (RCC) still remains unclear. In this study, we found that KIFC1 was upregulated in RCC tissues and is responsible for RCC tumorigenesis (p<0.001). The high expression of KIFC1 correlates with aggressive clinicopathologic parameters. Kaplan–Meier analysis suggested that KIFC1 was associated with poor survival prognosis in RCC. Silencing KIFC1 dramatically resulted in inhibition of proliferation, delayed the More >

Amanda Ikegami^*, Luiz Felipe S. Teixeira^*, Marina S. Braga^†, Matheus Henrique Dos S. Dias^‡, Eduardo C. Lopes^‡, Maria Helena Bellini^*

Oncology Research, Vol.26, No.5, pp. 743-751, 2018, DOI:10.3727/096504017X15120379906339

Abstract Renal cell carcinoma (RCC) accounts for approximately 2%–3% of human malignancies and is the most aggressive among urologic tumors. Biological heterogeneity, drug resistance, and chemotherapy side effects are the biggest obstacles to the effective treatment of RCC. The NF-kB transcription factor is one of several molecules identified to be responsible for the aggressive phenotype of this tumor. In the past decade, several studies have demonstrated the activation of NF-kB in RCC, and many have implicated NF-kB1 (p50) as an important molecule in tumor progression and metastasis. In the present study, a lentivirus was used to… More >

Haitao Song^*, Yanwei Rao^†, Gang Zhang^*, Xiangbo Kong^*

Oncology Research, Vol.26, No.3, pp. 457-466, 2018, DOI:10.3727/096504017X15035025554553

Abstract MicroRNAs (miRNAs) are emerging as pivotal regulators in the development and progression of various cancers, including renal cell carcinoma (RCC). MicroRNA-384 (miR-384) has been found to be an important cancer-related miRNA in several types of cancers. However, the role of miR-384 in RCC remains unclear. In this study, we aimed to investigate the potential function of miR-384 in regulating tumorigenesis in RCC. Here we found that miR-384 was significantly downregulated in RCC tissues and cell lines. Overexpression of miR-384 significantly inhibited the growth and invasion of RCC cells, whereas inhibition of miR-384 had the opposite More >

Dan Jiao^*, Man Wu^†, Lei Ji^‡, Feng Liu^§, Yingying Liu^§

Oncology Research, Vol.26, No.2, pp. 249-259, 2018, DOI:10.3727/096504017X14953948675430

Abstract Recent evidence suggests that dysregulation of microRNAs is associated with the development of multiple malignancies. miR-186 has been reported as a critical cancer regulator in several types of cancers. However, its functional significance and molecular mechanism underlying renal cell carcinoma (RCC) remain unknown. In this study, our results showed that miR-186 expression was dramatically downregulated in RCC tissues and cell lines compared to that in adjacent normal tissues and cell lines. Overexpression of miR-186 significantly inhibited cell growth, colony formation, and cell invasion; caused cell cycle arrest at the G₀/G₁ phase; and induced cell apoptosis as… More >

Feng Guo, Yaquan Liu

Oncology Research, Vol.26, No.2, pp. 183-189, 2018, DOI:10.3727/096504017X14837020772250

Abstract Transforming acidic coiled-coil protein 3 (TACC3) is a member of the TACC family and plays an important role in regulating cell mitosis, transcription, and tumorigenesis. However, the expression pattern and roles of TACC3 in renal cell carcinoma (RCC) remain unclear. The aim of this study was to investigate the role of TACC3 in RCC. We demonstrated overexpression of TACC3 in human RCC cell lines at both RNA and protein levels. Moreover, knockdown of TACC3 repressed RCC cell proliferation, migration, and invasion in vitro. In addition, knockdown of TACC3 inactivated PI3K/Akt signaling in RCC cells. Furthermore, More >

Zhenhua Zhao¹, Hui Liu¹, Junqing Hou, Tieqiang Li, Xinyi Du, Xiaolei Zhao, Wenchao Xu, Weibo Xu, Junkai Chang

Oncology Research, Vol.25, No.5, pp. 773-779, 2017, DOI:10.3727/096504016X14774889687280

Abstract Tumor protein D52 (TPD52) is a member of the TPD52-like protein family and plays different roles in various types of malignancies. However, its role in renal cell carcinoma (RCC) is still unclear. In this study, we investigated the role of TPD52 in RCC. The mechanism of TPD52 in RCC was also investigated. Our data demonstrated that the expression levels of TPD52 in both mRNA and protein were significantly decreased in RCC cells. Overexpression of TPD52 inhibited proliferation, migration, and invasion with decreased epithelial–mesenchymal transition (EMT) phenotype in RCC cells, as well as attenuated tumor growth More >

Xingtao Han^*†, Jinjian Yang^*, Zhankui Jia^*, Pengtao Wei^†, Han Zhang^†, Wenwei Lv^†, Jiantao Sun^†, Qingxiang Huo^†

Oncology Research, Vol.25, No.3, pp. 389-395, 2017, DOI:10.3727/096504016X14743324568129

Abstract The pre-mRNA splicing regulator serine–arginine protein kinase 1 (SRPK1), a member of the SR kinase family, plays an essential role in cancer development and various pathophysiological processes. However, its expression pattern and functions in renal cell carcinoma (RCC) remain unknown. Therefore, the aim of this study was to assess the role of SRPK1 in RCC. Our data showed that SRPK1 was significantly upregulated in human RCC tissues and cell lines. SRPK1 interference significantly inhibited the proliferation of RCC cells and inhibited tumor growth in vivo. In addition, SRPK1 interference also suppressed migration and invasion in More >